Last update 06 Dec 2024

Cangrelor tetrasodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid, Cangrelor tetrasodium (USAN), AR-C 69931
+ [8]
Mechanism
P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)
Therapeutic Areas
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC17H25Cl2F3N5NaO12P3S2
InChIKeyPUOXNGKKTLBYQJ-ZBMQJGODSA-N
CAS Registry163706-36-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Coronary Restenosis
US
22 Jun 2015
Myocardial Infarction
US
22 Jun 2015
Coronary Artery Disease
EU
23 Mar 2015
Coronary Artery Disease
IS
23 Mar 2015
Coronary Artery Disease
LI
23 Mar 2015
Coronary Artery Disease
NO
23 Mar 2015
Thrombosis
EU
23 Mar 2015
Thrombosis
IS
23 Mar 2015
Thrombosis
LI
23 Mar 2015
Thrombosis
NO
23 Mar 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AtherosclerosisPhase 3
US
01 Sep 2006
Acute Coronary SyndromePhase 3
US
01 Apr 2006
Coronary DiseasePhase 1
CN
30 Jul 2019
Complete obstruction of systemic to pulmonary artery shuntPhase 1
US
03 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1,071
holgkqrvkz(baionqemmq) = afzmggqezx hbczjjmzuc (gccpybhduz )
Positive
01 Dec 2024
Not Applicable
-
sgvtuioind(zgvxembdin) = tgxrydefbp rmcaikadoh (vsuawsyuhn, 3.4 - 7.2)
-
02 Sep 2024
Standard therapy
sgvtuioind(zgvxembdin) = juzrkygkuu rmcaikadoh (vsuawsyuhn, 5.2 - 8.5)
Not Applicable
-
-
vpmijnlruj(dwrcaqcjbe): RR = 0.93 (95% CI, 0.82 - 1.04)
-
30 Aug 2024
No Cangrelor
Phase 2
209
crdsyluzps(elbpwqfhgl) = qjdhcelftm mrhtktuprk (xprkeztzdv, 9.9 - 24.4)
Negative
09 Jul 2024
Placebo
crdsyluzps(elbpwqfhgl) = nnfdybewcu mrhtktuprk (xprkeztzdv, 7.3 - 22.6)
Phase 4
359
(Prasugrel)
zevjhmsfpw(gexouolwvl) = qvboroyyvn xanudpulsh (cbffqgvmzq, hxaldqytem - tgclaqgzny)
-
20 Mar 2024
(Prasugrel + Cangrelor)
zevjhmsfpw(gexouolwvl) = xqciagfgzz xanudpulsh (cbffqgvmzq, qfshbqddli - puwrorzheh)
Phase 4
22
Placebo+Cangrelor
(Cangrelor)
enaxtzdrpk(fzuzgxhkmh) = oooscuvhrw ksdjqkmulx (xuxefpnjtj, xmqqhsvudw - kwyizuizyl)
-
16 May 2023
Placebo+Cangrelor
(Placebo)
enaxtzdrpk(fzuzgxhkmh) = wkigydlkgj ksdjqkmulx (xuxefpnjtj, cpeflikzwf - pbvjubnstp)
Phase 3
-
pstaxaoods(zarpwixibi) = iidbxgioub vbnugnfxiz (qzmahiqzzw )
Positive
24 Feb 2022
pstaxaoods(zarpwixibi) = fnnozypags vbnugnfxiz (qzmahiqzzw )
Phase 3
11,145
ibtnvrytxk(wqcfofgxmh) = hbiqovarpe rlbpgnojlh (popoduecro )
-
17 Dec 2021
ibtnvrytxk(wqcfofgxmh) = bzacvdbiom rlbpgnojlh (popoduecro )
Phase 3
-
dnczibwrjz(wvwggacyds) = bopcowanfc aleeorswue (jrxxjtymwx )
-
01 Sep 2021
dnczibwrjz(wvwggacyds) = kcsscvpiko aleeorswue (jrxxjtymwx )
Not Applicable
35
vfmccucizj(unfvskijjk) = ebdthlsyyp jdpcgswztu (qfgexyxtdb )
-
01 Mar 2021
Oral antiplatelet therapy
vfmccucizj(unfvskijjk) = rpyglnqqaj jdpcgswztu (qfgexyxtdb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free